Algernon Health Inc.: Business Overview, Financials & Competitive Analysis
Algernon Health Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). Pre-revenue clinical-stage biotech with dual pipeline (drug development and neuroimaging infrastructure) facing significant capital constraints and equity dilution. The stock has declined 55.86% over the past year. Market capitalization stands at approximately $1.71M as of October 2026. Early-stage clinical programs with minimal revenue and ongoing capital raises indicate execution.
What is Algernon Health Inc.'s industry? Algernon Health Inc. (algernonhealth.com) operates in Biotechnology. AskCyborg classifies Algernon Health Inc. under Biotechnology in its company registry.
Algernon Health Inc. operates as a clinical stage pharmaceutical development company focused on developing therapeutic drugs for non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program...
Cyborg Score thesis
Pre-revenue clinical-stage biotech with dual pipeline (drug development and neuroimaging infrastructure) facing significant...
Read the full analyst-debate transcript →Get the Latest Algernon Health Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAlgernon Health Inc. Overview
Pro stress-test →Algernon Health Inc. operates as a clinical stage pharmaceutical development company focused on developing therapeutic drugs for non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke programs. The company was incorporated in 2015 and is headquartered in Vancouver, Canada.
Strategic Profile
Pro stress-test →The company's pipeline includes repirinast for chronic kidney disease treatment and N,N-Dimethyltryptamine for treating strokes and traumatic brain injuries. Algernon is expanding into neuroimaging infrastructure, opening brain-dedicated PET scanning clinics under the NovaScan Neuroimaging Clinics brand in the U.S., with the first location announced at HCA Florida University Medical Office Building in March 2026.
Competitive Landscape
Pro stress-test →Algernon operates in two distinct competitive spaces: (1) clinical-stage biotech drug development against larger pharmaceutical companies and specialized biotech focused on kidney disease, liver disease, and neurological indications; (2) specialized neuroimaging infrastructure competing with regional radiology providers and established neuroimaging networks. Limited direct competitors in rare disease indications, but capital constraints limit competitive reach.
Industry Context
Algernon Health Inc. operates in Biotechnology.
Key facts
Founded: 2015 · Headquarters: Vancouver, Canada · Employees: Not disclosed · Revenue: Estimated $0 (pre-revenue clinical-stage company) · Market cap: $1.71M